| Melanoma prognostics and personalized therapeutics at a crossroad. | |
| | |
MedLine Citation:
|
PMID: 23318787 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Melanoma has recently emerged as a poster child for targeted therapies and immunotherapies, with game-changing BRAF and immune checkpoint inhibitors now in clinical trials and with approved clinical indications. One highly anticipated use of novel therapeutic agents is in the adjuvant setting. Adjuvant BRAF and/or immune checkpoint inhibition may positively affect the survival of melanoma patients diagnosed at earlier stages but still at high risk for postsurgical relapses. BRAF V600 mutations and, potentially, melanoma-associated immunity are predictive biomarkers for responses to these novel therapies. Emerging evidence points to these predictive biomarkers doubling as prognostic biomarkers for high-risk stage III patients, promising to help stratify these patients for the application of novel adjuvant therapies. |
| | |
Authors:
|
Roger S Lo |
Related Documents
:
|
23376707 - Obesity is associated with worse outcomes in patients with t1 high grade urothelial car... 23564257 - Sex is not an independent risk factor for survival in differentiated thyroid cancer. 8175107 - Tumor localization as a prognostic factor in hepatocellular carcinoma. 23317107 - Amplification of the telomerase rna component gene as a new genetic marker for disease ... 20432747 - Cd20 positive childhood b-non hodgkin lymphoma (b-nhl): morphology, immunophenotype and... 10516747 - A phase ii trial of induction and consolidation therapy of acute myeloid leukemia with ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: The Journal of investigative dermatology Volume: 133 ISSN: 1523-1747 ISO Abbreviation: J. Invest. Dermatol. Publication Date: 2013 Feb |
Date Detail:
|
Created Date: 2013-01-15 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0426720 Medline TA: J Invest Dermatol Country: United States |
Other Details:
|
Languages: eng Pagination: 292-5 Citation Subset: IM |
Affiliation:
|
1] Department of Medicine, Division of Dermatology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA [2] Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Jonsson Comprehensive Cancer Center, Los Angeles, California, USA. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Dacarbazine in melanoma: from a chemotherapeutic drug to an immunomodulating agent.
Next Document: Nitroarachidonic acid prevents NADPH oxidase assembly and superoxide radical production in activated...